InsideCounsel
The future of preemption
July 29, 2015
For FDA (Food and Drug Administration)-regulated companies, federal preemption can provide a potentially powerful defense to state tort claims. In recent years, the U.S. Supreme Court has decided numerous preemption cases, each emphasizing the highly context-sensitive nature of the inquiry. Determining when preemption applies and how to deploy it to limit claims and to manage discovery requires a keen awareness of evolving doctrine and the regulatory record for the product at issue.
This article originally appeared on InsideCounsel on July 29, 2015.
Capabilities
Suggested News & Insights
Digital Health Transformation: A Practical Guide for Life Sciences CompaniesJanuary 18, 20232023 — The Year “Modernization” Comes to the U.S. Cosmetics IndustryJanuary 5, 2023U.S. Oversight Agencies Identify Program Integrity Risks Related to Increased Telehealth Usage During the PandemicDecember 13, 2022Switzerland Will Open Its Market for U.S. Food & Drug Administration (FDA) - Regulated Medical DevicesDecember 7, 2022One Step Forward, Two Steps Back: FDA’s Final Guidance on Clinical Decision Software Raises More Questions Than AnswersOctober 26, 2022New Swiss Data Protection Act – And a New Swiss-U.S. Trans-Atlantic Data Privacy Framework?October 25, 2022
- Stay Up To DateSubscribe to Sidley Publications
- Follow Sidley on Social MediaSocial Media Directory
